CX-516

From Wikipedia, the free encyclopedia

Jump to: navigation, search
CX-516
CX-516-2D-skeletal.svg
Systematic (IUPAC) name
6-(piperidin-1-ylcarbonyl)quinoxaline
Pharmacokinetic data
Biological half-life 45 minutes
Identifiers
CAS Number 154235-83-3 YesY
PubChem CID 148184
IUPHAR/BPS 4165
ChemSpider 130635 YesY
UNII Z5QU38B4V9 YesY
KEGG C13675 YesY
ChEMBL CHEMBL136800 YesY
Chemical data
Formula C14H15N3O
Molar mass 241.289 g/mol
  (verify)

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and is being developed by a collaboration of Cortex and Shire and Servier. It was researched as a treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.

See also[edit]

References[edit]